Kaj Blennow's research into M. Alzheimer recognized by the 2010 ECNP Neuropsychopharmacology Award

September 06, 2010

The European College of Neuropsychopharmacology (ECNP) is pleased to announce Kaj Blennow as the recipient of the 2010 ECNP Neuropsychopharmacology Award in recognition of his original and influential contributions to Alzheimer's disease research. The ECNP Neuropsychopharmacology Award is presented annually and recognises distinguished research in neuropsychopharmacology and closely related disciplines. The award is accompanied by a prize of € 20,000.

Kaj Blennow, Professor in Clinical Neurochemistry at the University of Gothenburg and Senior Consultant at the Neurochemical Laboratory of Sahlgrenska University Hospital, Gothenburg, Sweden, is one of the world's leading researchers in Alzheimer's disease. His work has focused on the development of laboratory measures for clinical diagnosis and therapy monitoring in Alzheimer's disease, with significant implications for both drug development and patient care.

"In the field of brain disorders, the development of good biomarkers can enhance the possibilities for early diagnostics and the measurement of treatment effects" Blennow said at the 23rd ECNP Congress in Amsterdam, the Netherlands. "In the future this could enable clinicians to diagnose and treat Alzheimer's disease before the person experiences any symptoms."

The scope of Blennow's research is extensive. In Alzheimer's disease, as well as biomarkers, it has embraced genetic mechanisms, neurochemical pathogenesis and neurotransmitter disturbances. He has also extended his neurochemical innovations into other fields of neuropsychopharmacology, such as schizophrenia and depression. "We clearly need new drug targets and innovative leads for novel therapies," Blennow commented on the recent closure of neuroscience labs of major pharmaceutical companies in Europe. "The basis for modern drug development, which has a strong tradition in Europe for more than 50 years improving the quality of life of people struck by brain disorders, has to be kept alive."

By 2040 the incidence of Alzheimer's disease is expected to double in Western Europe and triple in Eastern Europe, as Europe's population ages. Speaking on behalf of the ECNP 2010 Award Jury, Guy Goodwin of the University of Oxford, United Kingdom, said, "Kaj Blennow's contributions to addressing this growing public health challenge have been outstanding. We are delighted to be able to present him with this award."
-end-
ECNP is an independent scientific association established in 1987 to promote the translation of ground-breaking science discoveries into improved pharmacological treatments for mental disorders and enhanced public health. The 23rd ECNP Congress 2010 in Amsterdam, in which more than 7,000 registered participants from across the world met to discuss the latest advances in brain research, marks ECNP's ongoing commitment to alleviating the burden and suffering associated with mental disorders.

Contact:
Sonja Mak
ECNP Press Office
Tel. +43 1 405 5734
Fax +43 1 405 5734-16
E-mail: s.mak@update.europe.at

European College of Neuropsychopharmacology

Related Biomarkers Articles from Brightsurf:

Urgent need for blood-based biomarkers to diagnosis concussion
There is an urgent need for objective markers for diagnosing concussion, or mild traumatic brain injury.

Engineered bacteria churn out cancer biomarkers
A Cornell lab has created these very tools by commandeering simple, single-celled microorganisms - namely E. coli bacteria - and engineering them to explore the complex process of glycosylation and the functional role that protein-linked glycans play in health and disease.

Exercise induces secretion of biomarkers into sweat
The aim was to reveal the potential of microRNAs in sweat extracellular vesicles in monitoring exercise performance.

Phosphoprotein biomarkers to guide cancer therapy are identified
Researchers led by James Bibb, Ph.D., professor of surgery at the University of Alabama at Birmingham, suggest using a broader lens of post-translational modification analysis to identify new biomarkers of cancer drivers that may allow a much more precise prediction of patient responses to treatments.

Exhaled biomarkers can reveal lung disease
Using specialized nanoparticles, MIT engineers have developed a way to diagnose pneumonia or other lung diseases by analyzing the breath exhaled by the patient.

Race-specific lupus nephritis biomarkers
A University of Houston biomedical researcher has discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.

Semen miRNAs could be non-invasive biomarkers for prostate cancer
Researchers of the Human Molecular Genetics group at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr.

Scientists have found longevity biomarkers
An international group of scientists studied the effects of 17 different lifespan-extending interventions on gene activity in mice and discovered genetic biomarkers of longevity.

After concussion, biomarkers in the blood may help predict recovery time
A study of high school and college football players suggests that biomarkers in the blood may have potential use in identifying which players are more likely to need a longer recovery time after concussion, according to a study published in the July 3, 2019, online issue of Neurology, the medical journal of the American Academy of Neurology.

3D-printed device detects biomarkers of preterm birth
Preterm birth (PTB) -- defined as birth before the 37th week of gestation -- is the leading complication of pregnancy.

Read More: Biomarkers News and Biomarkers Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.